Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Approaching NK/T-cell lymphoma

Won-Seog Kim • 11 Jun 2022
EHA 2022
Lymphoma NK/T-cell Lymphoma Rare Diseases

In this video, Won Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, shares some insights into the treatment of NK/T-cell lymphoma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Won-Seog Kim

DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
1:35
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
Won-Seog Kim • 16 Jun 2023
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
1:07
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
Won-Seog Kim • 16 Jun 2023
Interim analysis of anbal-cel for R/R DLBCL
1:09
Interim analysis of anbal-cel for R/R DLBCL
Won-Seog Kim • 16 Jun 2023

Related Videos

Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
2:24
Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
Won-Seog Kim • 10 Dec 2025
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
1:13
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
Won-Seog Kim • 10 Dec 2025
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
5:31
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Won-Seog Kim • 10 Dec 2025
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
2:32
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
Won-Seog Kim • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals